LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
RoboCT, a technology-driven enterprise, takes technology innovation as its core driving force and is committed to exoskeleton robot technology, robot core components and intelligent control technology. They focus on the fields of rehabilitation and elderly care through the combination of human-computer interaction technology, artificial intelligence technology, data analysis and cloud computing, providing intelligent products and solutions for medical and healthcare institutions and individual users.
Website
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.